Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
Tessa Therapeutics today announced the appointment of Wilson W. Cheung as its chief financial officer…
Continue Reading-
-
Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting
Tessa Therapeutics today announced clinical data from the pilot stage of the ongoing Phase 2…
Continue Reading -
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)
Tessa Therapeutics today announced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X,…
Continue Reading -
Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting
Tessa Therapeutics today announced that data from its ongoing autologous and allogeneic cell therapy studies…
Continue Reading -
Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory
Tessa Therapeutics today announced a collaboration agreement with the Agency for Science Technology and Research’s…
Continue Reading -
Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma
Tessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being…
Continue Reading -
Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured in Podium Presentation at the ASGCT 24th Annual Meeting
Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of…
Continue Reading -
Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study
Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…
Continue Reading -
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3)…
Continue Reading -
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME)…
Continue Reading